Source: Eur Respir J, 50 (1) 1700409; 10.1183/13993003.00409-2017
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Wing Wai Yew, Denise P. Chan, Chi Chiu Leung, Ying Zhang, Ruibing Wang, Phoebe Ng, Simon M. Lee. Can toxicities induced by antituberculosis drugs be better managed in diabetic patients?. Eur Respir J, 50 (1) 1700409; 10.1183/13993003.00409-2017

Member's Comments

No comment yet.

Related content which might interest you: Severe adverse effects of antitubercular drugs and patient management Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Retrial of identical agents in patients with toxic hepatitis caused by first line antituberculosis drugs Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010 Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Which patients with COPD can potentially benefit from prophylactic use of antibiotics? Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 The side-effects of TB therapy: myth and reality Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties Year: 2005 Adverse effects of anti-tuberculosis drugs in hemodialysis patients Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Can asthma patients cope with new treatment regimens in Ukraine? Source: Eur Respir J 2003; 22: Suppl. 45, 409s Year: 2003 How often do asthma patients claim prescribed therapy? Source: International Congress 2017 – Asthma from childhood to adulthood and ACOS Year: 2017 Chemotherapy efficacy in TB patients resistant to major and reserve drugs Source: Eur Respir J 2005; 26: Suppl. 49, 648s Year: 2005 Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB Source: Eur Respir J 2006; 28: Suppl. 50, 8s Year: 2006 The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Frequency of adverse reactions to first-line anti-tuberculosis chemotherapy in patients with relapse(RTB)and newly diagnosed tuberculosis(NDTB) Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018 Adverse events in patients with MDR TB, treated by three types of the chemotherapy regimens Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 Is there a place for anti-remodelling drugs in asthma which may not display immediate clinical efficacy? Source: Eur Respir J 2004; 24: 1-2 Year: 2004 The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Side effects of antituberculosis drugs in treatment of patients with newly detected pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 197s Year: 2007 The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003